1-4 of 4
Irina A. Lukyanova, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Different Treatment Regimens, Optimal Time Points and Threshold Level While Minimal Residual Disease Evaluation in AML Patients

Tatiana I. Lobanova, MD, Irina V. Galtseva, PhD, Yuliya O. Davydova, Nikolay M. Kapranov, Vera V. Troitskaya, MD PhD, Irina A. Lukyanova, MD, Elena Parovichnikova, MD PhD, Sergei M. Kulikov, PhD, Larisa Kuzmina, PhD, Valery G. Savchenko, MD PhD academician
Journal: Blood
Blood (2018) 132 (Supplement 1): 2808.
https://doi.org/10.1182/blood-2018-99-114669
Published: 2018
Journal Articles

The MRD-Negativity Rate Measured By Flow Cytometry after the 1 st and the 2 nd Induction Course Among CR AML Patients from Different Cytogenetic Subgroups Does Not Differ Though the Morphological CR Achievement Does

Elena Parovichnikova, MD PhD, Vera V. Troitskaya, MD PhD, Irina V. Galtseva, PhD, Tatiana I. Lobanova, MD, Yuliya O. Davydova, Nikolay M. Kapranov, Andrey N. Sokolov, MD, Alina V. Kokhno, MD, PhD, Roman V. Tivikov, MD, Irina A. Lukyanova, MD, Tatiana N. Obukhova, MD PhD, Valery G. Savchenko, MD PhD academician
Journal: Blood
Blood (2018) 132 (Supplement 1): 1495.
https://doi.org/10.1182/blood-2018-99-116581
Published: 2018
Journal Articles

The Frequency and Impact of IKZF1 Deletions on Minimal Residual Disease in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated in Russian Acute Lymphoblastic Leukemia Study

Galina Baskhaeva, MD, Bella V. Biderman, PhD, Julia O. Davydova, Olga A. Gavrilina, MDPhD, Ksenija I. Zarubina, MD, Elena Stepanova, Irina A. Lukyanova, MD, Vera V. Troitskaya, MD PhD, Andrey Sudarikov, PhD, Irina V. Galtseva, MD PhD, Elena N. Parovichnikova, MD PhD, Valery Savchenko, MD PhD academician
Journal: Blood
Blood (2017) 130 (Supplement 1): 5002.
https://doi.org/10.1182/blood.V130.Suppl_1.5002.5002
Published: 2017
Journal Articles

Blinatumomab + Tyrosine Kinase Inhibitors with No Chemotherapy in BCR-ABL-Positive or IKZF1-Deleted or FLT3-ITD-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients: High Molecular Remission Rate and Toxicity Profile

Andrey N. Sokolov, MD, Elena N. Parovichnikova, MD PhD, Vera V. Troitskaya, MD PhD, Larisa A. Kuzmina, MD PhD, Irina V. Galtseva, Sergei M. Kulikov, PhD, Sergey N. Bondarenko, PhDMD, Julia O. Davidova, Nikolay M. Kapranov, Irina A. Lukyanova, MD, Tatiana I. Lobanova, MD, Ekaterina I. Usikova, MD, Ksenija I. Zarubina, MD, Valeriy G. Savchenko
Journal: Blood
Blood (2017) 130 (Supplement 1): 3884.
https://doi.org/10.1182/blood.V130.Suppl_1.3884.3884
Published: 2017